新华制药公告，近日收到国家药品监督管理局核准签发的阿仑膦酸钠口服溶液《药品注册证书》。该药 品适用于治疗绝经后妇女的骨质疏松症，以预防髋部和脊柱骨折（椎骨压缩性骨折）和男性骨质疏松以 增加骨量。2024年阿仑膦酸钠在包括中国公立医院、公立基层医疗机构、零售药店在内的三大终端销售 额达人民币7.2亿元。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received the drug registration certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration, indicating a significant advancement in its product offerings for osteoporosis treatment [1] Company Summary - The approval of Alendronate Sodium Oral Solution is aimed at treating osteoporosis in postmenopausal women and preventing hip and spinal fractures, as well as increasing bone mass in men with osteoporosis [1]

Core Points - Bavarian Nordic A/S has been awarded a joint procurement contract by the European Commission to supply up to 8 million doses of its MVA-BN smallpox/mpox vaccine [1][8] - The two-year agreement, which can be extended for an additional two years, aims to ensure continuous access to the vaccine across Europe, with participation confirmed from the European Commission and 20 countries [2][8] - Approximately 1.1 million doses have already been committed, with the first 750,000 doses expected to be supplied in 2026 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, particularly in the area of smallpox and mpox [7] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in several countries, including the U.S., Canada, and the EU [6] - The company has been collaborating with HERA since 2022 to support public health responses to mpox outbreaks and to stockpile vaccines against potential smallpox reemergence [5]

Group 1 - The core viewpoint of the articles highlights a significant surge in the innovative drug sector within the A-share market, particularly on October 31, where several stocks, including Shuyat and Sanofi, hit the 20% daily limit increase [1] - The A-share market experienced fluctuations, with the ChiNext index dropping over 2%, and the total trading volume in the Shanghai and Shenzhen markets reaching 2.32 trillion yuan, a decrease of 103.9 billion yuan compared to the previous trading day [1] - The introduction of the "Commercial Insurance Innovative Drug Directory" mechanism during the national medical insurance negotiations is expected to benefit innovative drugs that are highly innovative and clinically valuable but are not yet included in the basic directory [1] Group 2 - According to Guosen Securities, the Chinese innovative drug industry is showing a long-term positive development trend, particularly evident in the explosive growth of BD transactions in recent years [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners overseas and subsequent global clinical data readings enhancing the certainty of commercialization in the global market [2] - The long-term logic of investing in innovative drugs is favored, with a focus on stocks that are showing signs of bottom reversal [2]

Core Insights - The prolonged slowdown in biotechnology startup funding has created opportunities for corporate venture firms to invest in privately held companies [1] - Corporate venture activity has surged in 2025, with firms like Novo Holdings, Eli Lilly, and Sanofi being among the most active investors [2][3] Corporate Venture Activity - Novo Holdings has participated in 18 private venture rounds in 2025, leading among tracked firms, while Eli Lilly and Sanofi Ventures have each contributed to 13 rounds [2] - Corporate venture investors are increasingly important to the biotech ecosystem, with many pharmaceutical companies, including Pfizer, Novartis, Roche, and Johnson & Johnson, having venture arms that fund early-stage life science companies [3] Funding Sources and Strategies - Unlike traditional biotech investors, corporate venture arms utilize capital from their parent corporations, allowing for a long-term investment strategy rather than a focus on quick returns [4] - Companies like Lilly and Novo Nordisk have gained significant revenue from their GLP-1 medicines, providing them with more capital for investments [5] Market Dynamics - The presence of corporate venture firms enhances the attractiveness of young drug companies to other investors, with a report indicating that at least 70% of biopharma IPOs since 2022 included a corporate venture investor, all raising at least $50 million [6]

Core Insights - Vistin Pharma ASA reported a revenue increase in Q3 2025, reaching MNOK 109, up from MNOK 106 in Q3 2024, driven by a 10% higher sales volume [1] - Year-to-date revenue for 2025 is MNOK 342, an 8% increase from MNOK 316 in the same period last year [1] - The company's EBITDA for Q3 2025 was MNOK 28, slightly down from MNOK 29 in Q3 2024, impacted by lower global metformin prices [1] - Year-to-date EBITDA for 2025 stands at MNOK 89, a 16% increase from MNOK 77 in YTD 2024 [1] - Net profit for Q3 2025 was MNOK 18.5, compared to MNOK 16.6 in the previous year [2] - The company achieved an all-time high production volume of 1,600 MT of metformin in the quarter [2] Financial Performance - Q3 2025 revenue: MNOK 109, up 2.8% from Q3 2024 [1] - YTD 2025 revenue: MNOK 342, an 8% increase from YTD 2024 [1] - Q3 2025 EBITDA: MNOK 28, down from MNOK 29 in Q3 2024 [1] - YTD 2025 EBITDA: MNOK 89, up 16% from YTD 2024 [1] - Q3 2025 net profit: MNOK 18.5, compared to MNOK 16.6 in Q3 2024 [2] Production and Operations - All-time high production volume of metformin: 1,600 MT in Q3 2025 [2]

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total ...

Core Viewpoint - Amazon's strong quarterly profit report significantly boosted the U.S. stock market, leading to a winning week and month for major indices [1][2]. Group 1: Amazon's Performance - Amazon's stock surged by 9.6% after reporting a profit that exceeded analysts' expectations, with CEO Andy Jassy noting accelerated growth in its cloud-computing business [2]. - The company's market capitalization of approximately $2.4 trillion means its stock movements have a substantial impact on the S&P 500, which would have declined without Amazon's performance [2]. Group 2: Other Influential Stocks - Apple, valued at over $4 trillion, had a less pronounced effect on the market, finishing down 0.4% despite reporting better-than-expected profits [3][4]. - Reddit's stock increased by 7.5% after also reporting stronger profit and revenue than anticipated [4]. - Coinbase Global's stock rose by 4.6% following a profit report that topped expectations [5]. Group 3: Market Trends and Expectations - Netflix announced a 10-for-1 stock split, which could make its shares more affordable while maintaining the same total value for investors, leading to a 2.7% increase in its stock price [5]. - AbbVie experienced a 4.5% decline despite reporting stronger-than-expected profits, as analysts noted that its profit growth was not as robust as before [6]. - There is increasing pressure on companies to deliver significant profit growth to justify the high valuations seen in the stock market since April [7].

Savara Inc. (NASDAQ:SVRA) is one of the best stocks under $5 with highest upside potential. On October 23, Citizens JMP lifted its price target on Savara Inc. (NASDAQ:SVRA) to $11 from $8 while keeping an Outperform rating on the shares. The firm told investors in a research note that its pulmonologist survey shows solid demand for Molbreevi, with 60% of those surveyed expressing an inclination to use it. This, according to Citizens JMP, should mean blockbuster sales, with Savara Inc. (NASDAQ:SVRA) set t ...

Group 1 - Pfizer Inc. has a current yield of 7% and recently acquired Seagen, but the drug stocks, including Pfizer, are facing significant challenges [1][2] - The market perception of Pfizer is that it lacks compelling offerings, with the Seagen acquisition not meeting expectations [2] - Despite the challenges, there is a belief that Pfizer could still find a way to improve its situation, similar to how various players in the cholesterol market have succeeded [2]